Biotech Stocks To Keep An Eye On – November 4th

04 Nov 2026, 17:15 by Danessa Lincoln · The Markets Daily

Moderna, Amgen, AbbVie, Gilead Sciences, Regeneron Pharmaceuticals, Madrigal Pharmaceuticals, and Natera are the seven Biotech stocks to watch today, according to MarketBeat’s stock screener tool. Biotech stocks are shares of publicly traded companies that develop products and technologies based on biology, such as prescription drugs, vaccines, gene therapies, and diagnostic tests. For investors, these stocks can offer significant growth potential but often carry substantial risk because their success may depend on clinical-trial results, regulatory approvals, funding, and commercialization. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Moderna (MRNA)

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.

NASDAQ:MRNA traded up $21.54 during mid-day trading on Wednesday, hitting $249.98. 6,906,422 shares of the company’s stock traded hands, compared to its average volume of 12,597,973. The firm has a market capitalization of $99.80 billion, a price-to-earnings ratio of -31.25 and a beta of 1.16. Moderna has a 12 month low of $22.28 and a 12 month high of $254.48. The firm has a 50 day moving average of $185.79 and a two-hundred day moving average of $88.36. The company has a current ratio of 2.29, a quick ratio of 2.18 and a debt-to-equity ratio of 0.09.

Read Our Latest Research Report on MRNA

Amgen (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.

Shares of AMGN stock traded up $16.94 during mid-day trading on Wednesday, reaching $478.20. The stock had a trading volume of 1,634,265 shares, compared to its average volume of 2,743,492. The firm’s 50 day simple moving average is $420.83 and its 200 day simple moving average is $376.16. The firm has a market cap of $258.53 billion, a PE ratio of 29.71, a P/E/G ratio of 3.41 and a beta of 0.43. Amgen has a one year low of $302.13 and a one year high of $482.00. The company has a quick ratio of 1.13, a current ratio of 1.37 and a debt-to-equity ratio of 4.44.

Read Our Latest Research Report on AMGN

AbbVie (ABBV)

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.

ABBV traded up $2.83 during midday trading on Wednesday, reaching $288.82. 2,674,422 shares of the company’s stock were exchanged, compared to its average volume of 6,318,158. The business has a 50-day simple moving average of $270.23 and a two-hundred day simple moving average of $237.89. AbbVie has a one year low of $190.75 and a one year high of $298.74. The firm has a market capitalization of $510.29 billion, a price-to-earnings ratio of 49.65, a price-to-earnings-growth ratio of 1.31 and a beta of 0.20.

Read Our Latest Research Report on ABBV

Gilead Sciences (GILD)

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.

GILD stock traded up $5.62 during trading on Wednesday, hitting $173.09. 2,995,249 shares of the stock traded hands, compared to its average volume of 6,804,242. The company has a 50 day simple moving average of $151.77 and a 200 day simple moving average of $140.25. The company has a current ratio of 1.38, a quick ratio of 0.95 and a debt-to-equity ratio of 1.84. Gilead Sciences has a one year low of $116.88 and a one year high of $175.65. The stock has a market cap of $214.68 billion, a price-to-earnings ratio of -54.77 and a beta of 0.35.

Read Our Latest Research Report on GILD

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

NASDAQ REGN traded down $20.63 on Wednesday, hitting $952.73. 471,537 shares of the company were exchanged, compared to its average volume of 826,337. The company has a market cap of $98.09 billion, a P/E ratio of 21.10, a P/E/G ratio of 1.51 and a beta of 0.10. Regeneron Pharmaceuticals has a 1-year low of $591.52 and a 1-year high of $991.73. The company has a current ratio of 3.35, a quick ratio of 3.66 and a debt-to-equity ratio of 0.06. The firm has a 50 day moving average of $798.74 and a two-hundred day moving average of $740.16.

Read Our Latest Research Report on REGN

Madrigal Pharmaceuticals (MDGL)

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH.

Shares of Madrigal Pharmaceuticals stock traded down $10.89 on Wednesday, hitting $385.43. 1,123,924 shares of the company’s stock traded hands, compared to its average volume of 340,282. The stock has a market capitalization of $8.90 billion, a PE ratio of -29.56 and a beta of -0.98. The firm’s 50-day moving average price is $494.64 and its two-hundred day moving average price is $498.92. The company has a debt-to-equity ratio of 0.65, a current ratio of 3.20 and a quick ratio of 2.94. Madrigal Pharmaceuticals has a one year low of $353.54 and a one year high of $615.00.

Read Our Latest Research Report on MDGL

Natera (NTRA)

Natera, Inc., a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Shares of NASDAQ NTRA traded down $11.00 during midday trading on Wednesday, reaching $377.63. 1,037,404 shares of the stock were exchanged, compared to its average volume of 1,419,996. The company has a market capitalization of $54.43 billion, a price-to-earnings ratio of -276.56 and a beta of 1.55. The business has a 50-day simple moving average of $379.22 and a two-hundred day simple moving average of $267.89. Natera has a 12 month low of $181.00 and a 12 month high of $437.41.

Read Our Latest Research Report on NTRA